Capricor Therapeutics is trading 6.61% up now at $10.56 after Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $25 from $2.
- The upgrade cited FDA acceptance of a major Deramiocel BLA amendment, 24-month HOPE-3 extension data, and a refined upper-limb-function indication.
- The FDA review extension to November 22, 2026 does not guarantee approval, but regulatory progress and bullish analyst revisions are supporting continued buying.